Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2019-09-27 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses the scheduling of the company's 2019 Annual Meeting of Stockholders, including the date of the meeting, record date for voting, and deadlines for shareholder proposals and director nominations. It does not contain financial statements or detailed financial analysis, nor is it a full annual or quarterly report. It is an announcement related to shareholder meeting logistics and proxy material deadlines. This fits best under Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like AGM Information or Proxy Solicitation. The document length is under 5,000 characters, and it is not a report publication announcement or certification. Therefore, the classification is RNS with high confidence.
2019-09-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes standard 8-K form headers, company identification, and mentions a press release attached as Exhibit 99.1. The document length is 2913 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. There are no financial statements or substantive financial data included in the text. The document does not contain quarterly or annual financial results, management discussion, or audit information. It is a regulatory filing used to disclose material events to the market. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2019-09-17 English
FORM 4 SUBMISSION
Director's Dealing
2019-09-09 English
FORM 4 SUBMISSION
Director's Dealing
2019-09-09 English
Regulatory Filings 2019
Regulatory Filings
2019-08-23 English
Regulatory Filings 2019
Regulatory Filings
2019-08-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.